JP2008526189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526189A5 JP2008526189A5 JP2007548838A JP2007548838A JP2008526189A5 JP 2008526189 A5 JP2008526189 A5 JP 2008526189A5 JP 2007548838 A JP2007548838 A JP 2007548838A JP 2007548838 A JP2007548838 A JP 2007548838A JP 2008526189 A5 JP2008526189 A5 JP 2008526189A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- nucleic acid
- promoter
- cell
- acid encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims 79
- 150000007523 nucleic acids Chemical class 0.000 claims 54
- 108020004707 nucleic acids Proteins 0.000 claims 53
- 102000039446 nucleic acids Human genes 0.000 claims 53
- 210000004027 cell Anatomy 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 17
- 108010078791 Carrier Proteins Proteins 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 230000032823 cell division Effects 0.000 claims 13
- 230000002950 deficient Effects 0.000 claims 11
- 230000005855 radiation Effects 0.000 claims 11
- 101710155188 Hexon-interlacing protein Proteins 0.000 claims 10
- 210000004881 tumor cell Anatomy 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 230000010076 replication Effects 0.000 claims 6
- 230000014509 gene expression Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 230000002074 deregulated effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 claims 3
- 102000004594 DNA Polymerase I Human genes 0.000 claims 3
- 108010017826 DNA Polymerase I Proteins 0.000 claims 3
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims 3
- 230000022131 cell cycle Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 3
- 230000029812 viral genome replication Effects 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 claims 2
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 2
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 2
- 206010020843 Hyperthermia Diseases 0.000 claims 2
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 108010082820 apicidin Proteins 0.000 claims 2
- 229930186608 apicidin Natural products 0.000 claims 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 2
- 229960003094 belinostat Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 2
- 230000036031 hyperthermia Effects 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 claims 1
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101150005585 E3 gene Proteins 0.000 claims 1
- 101150066038 E4 gene Proteins 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims 1
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- -1 anticalins Proteins 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 238000012512 characterization method Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims 1
- 229950009213 rubitecan Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004063662.1 | 2004-12-31 | ||
| DE102004063662 | 2004-12-31 | ||
| PCT/EP2006/000010 WO2006070024A2 (de) | 2004-12-31 | 2006-01-02 | E1 -minus adenoviren und deren verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526189A JP2008526189A (ja) | 2008-07-24 |
| JP2008526189A5 true JP2008526189A5 (https=) | 2009-02-19 |
| JP5435871B2 JP5435871B2 (ja) | 2014-03-05 |
Family
ID=36615284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548838A Expired - Lifetime JP5435871B2 (ja) | 2004-12-31 | 2006-01-02 | Ｅ１−マイナスアデノウイルス及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20090232800A1 (https=) |
| EP (1) | EP1830864A2 (https=) |
| JP (1) | JP5435871B2 (https=) |
| CA (1) | CA2610360A1 (https=) |
| WO (1) | WO2006070024A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2487811A1 (en) | 2002-05-27 | 2003-12-04 | Per Sonne Holm | Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors |
| EP1689445B1 (de) | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| JP5584393B2 (ja) | 2004-12-31 | 2014-09-03 | ホルム，ペル・ゾンネ | 動物細胞における多剤耐性を逆転させる方法 |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| CN101189003B (zh) | 2005-05-13 | 2012-02-08 | 托波塔吉特英国有限公司 | Hdac抑制剂的药物制剂 |
| JP5377968B2 (ja) * | 2005-11-10 | 2013-12-25 | トポターゲット ユーケー リミテッド | 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤 |
| JP2010540426A (ja) * | 2007-09-25 | 2010-12-24 | トポターゲット ユーケー リミテッド | 特定のヒドロキサム酸化合物の合成方法 |
| AU2009220942B2 (en) * | 2008-03-07 | 2015-05-28 | Onxeo Dk, Branch Of Onxeo S.A., France | Methods of treatment employing prolonged continuous infusion of Belinostat |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| KR102020018B1 (ko) | 2009-03-02 | 2019-09-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이 |
| JP2011111435A (ja) * | 2009-11-30 | 2011-06-09 | Joy Up:Kk | 神経芽腫又は膠芽腫の治療薬 |
| AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| KR20250081944A (ko) | 2014-09-24 | 2025-06-05 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| EP4155411A1 (en) | 2016-02-23 | 2023-03-29 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CN118307682A (zh) * | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| MX2020010499A (es) | 2018-04-09 | 2020-10-28 | Salk Inst For Biological Studi | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5707618A (en) * | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| AU718772B2 (en) * | 1995-03-24 | 2000-04-20 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| US6955808B2 (en) * | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| DK1497440T3 (da) * | 2002-04-25 | 2008-12-01 | Crucell Holland Bv | Stabile adenovirale vektorer og fremgangsmåder til propagering deraf |
| CA2487811A1 (en) * | 2002-05-27 | 2003-12-04 | Per Sonne Holm | Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors |
| EP1554375B1 (de) * | 2002-10-15 | 2018-08-22 | Per Sonne Holm | Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon |
| RU2393221C2 (ru) * | 2002-10-15 | 2010-06-27 | Пер Сонне ХОЛЬМ | Аденовирус с обращенной генной экспрессией и его применение |
| WO2004083244A2 (en) * | 2003-03-19 | 2004-09-30 | Isogenis, Inc. | Specific inhibition of allograft rejection |
| EP1689446B1 (de) * | 2003-11-14 | 2015-01-07 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| EP1689445B1 (de) * | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| CA2590943C (en) * | 2004-12-13 | 2013-10-22 | Canji, Inc. | Cell lines for production of replication-defective adenovirus |
| JP5584393B2 (ja) * | 2004-12-31 | 2014-09-03 | ホルム，ペル・ゾンネ | 動物細胞における多剤耐性を逆転させる方法 |
| US20070292396A1 (en) * | 2006-03-02 | 2007-12-20 | Juan Fueyo | Combination therapy with oncolytic adenovirus |
-
2006
- 2006-01-02 EP EP06700409A patent/EP1830864A2/de not_active Ceased
- 2006-01-02 US US11/813,089 patent/US20090232800A1/en not_active Abandoned
- 2006-01-02 JP JP2007548838A patent/JP5435871B2/ja not_active Expired - Lifetime
- 2006-01-02 WO PCT/EP2006/000010 patent/WO2006070024A2/de not_active Ceased
- 2006-01-02 CA CA002610360A patent/CA2610360A1/en not_active Abandoned
-
2011
- 2011-07-19 US US13/186,290 patent/US20120039877A1/en not_active Abandoned
-
2017
- 2017-03-17 US US15/462,133 patent/US20170190752A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526189A5 (https=) | ||
| US11268073B2 (en) | Use of adenovirus and nucleic acids coding therefor | |
| JP5873893B2 (ja) | アデノウイルスおよびそれをコードしている核酸の新たな使用 | |
| JP5618896B2 (ja) | 新規アデノウイルス、それをコードする核酸及びその使用 | |
| JP2008526188A5 (https=) | ||
| AU2010257327C1 (en) | Adenovirus expressing genes in reverse order and use thereof | |
| JP5435871B2 (ja) | Ｅ１−マイナスアデノウイルス及びその使用 | |
| JP2007511212A5 (https=) | ||
| JP2006512284A5 (https=) | ||
| WO2006070023A2 (en) | Method for reversing multiple resistance in animal cells | |
| AU2015201828B2 (en) | Novel use of adenoviruses and nucleic acids coding therefor |